Andra AP fonden Increases Holdings in Axon Enterprise, Inc $AXON

Andra AP fonden increased its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 38.8% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 23,973 shares of the biotechnology company’s stock after purchasing an additional 6,700 shares during the period. Andra AP fonden’s holdings in Axon Enterprise were worth $17,204,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Stone House Investment Management LLC bought a new position in shares of Axon Enterprise in the third quarter valued at approximately $29,000. New Millennium Group LLC purchased a new stake in Axon Enterprise in the 3rd quarter worth approximately $29,000. Root Financial Partners LLC bought a new position in Axon Enterprise in the 3rd quarter valued at $34,000. Darwin Wealth Management LLC purchased a new position in shares of Axon Enterprise during the 2nd quarter valued at $37,000. Finally, NewSquare Capital LLC grew its position in shares of Axon Enterprise by 96.2% during the 2nd quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 25 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on AXON shares. Morgan Stanley lowered their price objective on Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating on the stock in a research report on Wednesday. Needham & Company LLC decreased their target price on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. William Blair reaffirmed an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, February 3rd. The Goldman Sachs Group cut their price objective on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Finally, UBS Group decreased their price objective on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a research report on Wednesday. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $762.93.

Axon Enterprise Price Performance

Shares of AXON stock opened at $542.40 on Friday. The firm has a market cap of $43.61 billion, a P/E ratio of 356.84, a P/E/G ratio of 16.57 and a beta of 1.48. Axon Enterprise, Inc has a fifty-two week low of $396.41 and a fifty-two week high of $885.91. The business’s 50 day moving average price is $537.92 and its 200-day moving average price is $625.54. The company has a debt-to-equity ratio of 0.53, a quick ratio of 2.89 and a current ratio of 2.53.

Axon Enterprise (NASDAQ:AXON) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The company had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. During the same quarter in the prior year, the company earned $2.08 earnings per share. The firm’s revenue for the quarter was up 38.5% on a year-over-year basis. On average, equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

Insiders Place Their Bets

In other news, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $551.92, for a total value of $5,519,200.00. Following the completion of the sale, the chief executive officer directly owned 3,110,997 shares of the company’s stock, valued at approximately $1,717,021,464.24. This trade represents a 0.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Joshua Isner sold 20,000 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the transaction, the president owned 249,502 shares in the company, valued at $137,874,805.20. This represents a 7.42% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 58,040 shares of company stock worth $32,251,738. Company insiders own 4.40% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.